US OptionsDetailed Quotes
GERN241115P2500
- 0.00
- 0.000.00%
15min DelayClose Nov 7 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV41.72%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma5.72Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Geron Stock Discussion
Sign in to post a comment
$Geron (GERN.US)$ Reuters· 2 mins ago
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
1
6
$Geron (GERN.US)$ Reuters· 1 mins ago
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
2
1
$Geron (GERN.US)$ Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
1
$Geron (GERN.US)$ Really wants to just chill at 4
$Geron (GERN.US)$ For those who is new to this company, here is a summary: JNJ paid 250M a year to co develop the drug 5 years ago. They didn’t want to continue the second year which the price was low 5 n drop to lowest of 1.30 in the next 2 years. Gern continue to drug development with the 250M from JNJ to get it FDA approval few months ago to which they raised 450M for reserve cash. The stock went up to hitting 52 weeks high of 5.34 in the next month or two of FDA approval. You now are caught...
$Geron (GERN.US)$ this is the month I have been waiting for since Feb as per news on 1) partnership or 2) buy out. Go alone will have its risk n reward which they secure 420M to do it to last early 2026. If its #1 then expect stock 7-8 range, #2- Like to see 10-15 range.Lets beat my #1 niotech buyout imgn return with this prediction.
3
$Geron (GERN.US)$ Geron Announces Updated Nccn Guidelines® Recommending Rytelo™ (Imetelstat) for the Treatment of Symptomatic Anemia in Patients With Lower-Risk Mds
1
4
No comment yet
dSuu : looks like a fight already, gl big profits
Trytosaveabit OP dSuu : Yup yup! Thanks you too![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
dSuu : time for fun to start already lol
Trytosaveabit OP dSuu : Hehehe! I just wish float was a lot smaller. Hehehe! But as FREY showed us yesterday! It don’t always need to be small to move great! Hehehe
dSuu : yeah that float is large, but any and everything is possible
View more comments...